dc.contributor.author | Gilbert, Luke Andrew | |
dc.contributor.author | Hemann, Michael | |
dc.date.accessioned | 2012-10-05T18:26:06Z | |
dc.date.available | 2012-10-05T18:26:06Z | |
dc.date.issued | 2011-07 | |
dc.date.submitted | 2011-04 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/73659 | |
dc.description.abstract | Chemotherapeutic regimens involve the systemic administration of genotoxic compounds that induce cancer cell death via well-established DNA damage response signaling networks. Less understood is how the treatment of other cell types within the tumor microenvironment affects the therapeutic response. Here we discuss recent work that shows that tumor-adjacent cells can respond to genotoxic stress by activating a paracrine secretory program. Although this secretory response serves to protect progenitor cells and promote tissue regeneration in conditions of cellular stress, it can also be coopted by tumor cells to survive frontline chemotherapy. Thus, local prosurvival signaling may present a fundamental barrier to tumor clearance by genotoxic agents, suggesting that effective treatments need to target both cancer cells and the tumor microenvironment. Cancer Res; 71(15); 5062–6. | en_US |
dc.description.sponsorship | National Institutes of Health (U.S.) (RO1 CA128803) | en_US |
dc.description.sponsorship | Massachusetts Institute of Technology. Ludwig Center for Molecular Oncology (Ludwig Graduate Fellowship) | en_US |
dc.language.iso | en_US | |
dc.publisher | American Association for Cancer Research | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1158/0008-5472.can-11-0277 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike 3.0 | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
dc.source | PMC | en_US |
dc.title | Chemotherapeutic Resistance: Surviving Stressful Situations | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Gilbert, L. A., and M. T. Hemann. “Chemotherapeutic Resistance: Surviving Stressful Situations.” Cancer Research 71.15 (2011): 5062–5066. Web. | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
dc.contributor.mitauthor | Gilbert, Luke Andrew | |
dc.contributor.mitauthor | Hemann, Michael | |
dc.relation.journal | Cancer Research | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Gilbert, L. A.; Hemann, M. T. | en |
mit.license | OPEN_ACCESS_POLICY | en_US |
mit.metadata.status | Complete | |